

Moxacil ® 250mg capsules
Amoxicillin (as Trihydrate) BP 500mg

Qualitative and quantitative composition:

Each capsule contains :Amoxicillin (as Trihydrate) BP 500mg

Pharmacology

Pharmacotherapeutic group: Penicillins with extended spectrum; ATC code: J01CA04.

Mechanism of action

Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bacterial peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death.

Amoxicillin is susceptible to degradation by beta-lactamases produced by resistant bacteria and therefore the spectrum of activity of amoxicillin alone does not include organisms which produce these enzymes.

Pharmacokinetic properties

Amoxicillin is stable in the acid gastric secretion and is rapidly absorbed from the gastrointestinal tract after oral administration. The presence of food does not interfere with this process. Peak plasma concentrations are obtained in about two hours

Following oral administration, amoxicillin is approximately 70% bioavailable.

The time to peak plasma concentration (T_{max}) is approximately one hour.

Distribution : About 18% of total plasma amoxicillin is bound to protein and the apparent volume of distribution is around 0.3 to 0.4 l/kg. Amoxicillin, like most penicillins, can be detected in breast milk, Also has been shown to cross the placental barrier

Biotransformation : Amoxicillin is partly excreted in the urine as the inactive penicilloic acid in quantities equivalent to up to 10 to 25% of the initial dose.

Elimination : The major route of elimination for amoxicillin is via the kidney.

mean elimination half-life of approximately one hour and a mean total clearance of approximately 25 l/hour in healthy subjects. Approximately 60 to 70% of the amoxicillin is excreted unchanged in urine during the first 6 hours after administration of a single 250 mg or 500 mg dose of amoxicillin. Various studies have found the urinary excretion to be 50-85% for amoxicillin over a 24 hour period.

The elimination half-life of amoxicillin is similar for children aged around 3 months to 2 years and older children and adults. For very young children (including preterm newborns) in the first week of life the interval of administration should not exceed twice daily administration due to immaturity of the renal pathway of elimination. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

The total serum clearance of amoxicillin decreases proportionately with decreasing renal function

Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals.

Therapeutic indications:

Amoxicillin is indicated for the treatment of the following infections in adults and children

Acute bacterial sinusitis, Acute otitis media, Acute streptococcal tonsillitis and pharyngitis, Acute exacerbations of chronic bronchitis, Community acquired pneumonia, Acute cystitis, Asymptomatic bacteriuria in pregnancy, Acute pyelonephritis, Typhoid and paratyphoid fever, Dental abscess with spreading cellulitis, Prosthetic joint infections, Helicobacter pylori eradication and Lyme disease .

Amoxicillin is also indicated for the prophylaxis of endocarditis.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Posology and method of administration:

Method of administration: Capsules for oral administration only

Swallow with water without opening capsule.

Posology

Adults and children ≥ 40 kg

Acute bacterial sinusitis, *Asymptomatic bacteriuria in pregnancy*, *Acute pyelonephritis*, *Dental abscess with spreading cellulitis* and *Acute cystitis*: 250 mg to 500 mg every 8 hours or 750 mg to 1 g every 12 hours

For severe infections 750 mg to 1 g every 8 hours

Acute cystitis may be treated with 3 g twice daily for one day

Acute otitis media, *Acute streptococcal tonsillitis and pharyngitis* and *Acute exacerbations of chronic bronchitis*:

500 mg every 8 hours, 750 mg to 1 g every 12 hours

For severe infections 750 mg to 1 g every 8 hours for 10 days

Community acquired pneumonia: 500 mg to 1 g every 8 hours

Typhoid and paratyphoid fever: 500 mg to 2 g every 8 hours

Prosthetic joint infections: 500 mg to 1 g every 8 hours

Prophylaxis of endocarditis: 2 g orally, single dose 30 to 60 minutes before procedure

Helicobacter pylori eradication: 750 mg to 1 g twice daily in combination with a proton pump inhibitor

(e.g. omeprazole, lansoprazole) and another antibiotic (e.g. clarithromycin, metronidazole) for 7 days

Lyme disease: Early stage: 500 mg to 1 g every 8 hours up to a maximum of 4 g/day in divided doses for 14 days (10 to 21 days)

Late stage (systemic involvement): 500 mg to 2 g every 8 hours up to a maximum of 6 g/day in divided doses for 10 to 30 days

Children < 40 kg

Amoxicillin Paediatric Suspension is recommended for children under six months of age.

Recommended doses:

Acute bacterial sinusitis, *Acute otitis media*, *Community acquired pneumonia*, *Acute cystitis*, *Acute pyelonephritis* and *Dental abscess with spreading cellulitis*: 20 to 90 mg/kg/day in divided doses (Twice daily)

Acute streptococcal tonsillitis and pharyngitis: 40 to 90 mg/kg/day in divided doses (Twice daily)

Typhoid and paratyphoid fever: 100 mg/kg/day in three divided doses

Prophylaxis of endocarditis: 50 mg/kg orally, single dose 30 to 60 minutes before procedure

Lyme disease: Early stage: 25 to 50 mg/kg/day in three divided doses for 10 to 21 days

Late stage (systemic involvement): 100 mg/kg/day in three divided doses for 10 to 30 days

Renal impairment

GFR (ml/min) greater than 30: Adults and children ≥ 40 kg

:Children < 40 kg# :no adjustment necessary

GFR (ml/min) 10 to 30: Adults and children ≥ 40 kg Maximum 500 mg twice daily

:Children < 40 kg: 15 mg/kg given twice daily (maximum 500 mg twice daily)

GFR (ml/min) Less than 10: Adults and children ≥ 40 kg Maximum 500 mg/day.

:Children < 40 kg# 15 mg/kg given as a single daily dose (maximum 500 mg)

In patients receiving haemodialysis

Adults and children over 40 kg: 500 mg every 24 h

Prior to haemodialysis one additional dose of 500 mg should be administered. In order to restore circulating drug levels, another dose of 500 mg should be administered after haemodialysis.

Children under 40 kg: 15 mg/kg/day given as a single daily dose (maximum 500 mg).

Prior to haemodialysis one additional dose of 15 mg/kg should be administered. In order to restore circulating drug levels, another dose of 15 mg/kg should be administered after haemodialysis

In patients receiving peritoneal dialysis

Amoxicillin maximum 500 mg/day.

Hepatic impairment: Dose with caution and monitor hepatic function at regular intervals

Elderly: No dose adjustment is considered necessary.

Contraindications:

Use with caution in patients with a known history of allergy to penicillin's or to any of the excipients

It should not be administered to patients with infectious mononucleosis (glandular fever) since they are especially susceptible to amoxicillin-induced skin rashes.

Special warnings and precautions for use:

Use with caution in patients with a known history of allergy to penicillin's, cephalosporins or other beta-lactam agents
Amoxicillin is not suitable for the treatment of some types of infection unless the pathogen is already documented and known to be susceptible or there is a very high likelihood that the pathogen would be suitable for treatment with amoxicillin
This particularly applies when considering the treatment of patients with urinary tract infections and severe infections of the ear, nose and throat.

Convulsions may occur in patients with impaired renal function or in those receiving high doses or in patients with predisposing factors (e.g. history of seizures, treated epilepsy or meningeal disorders)

In patients with renal impairment, the dose should be adjusted according to the degree of impairment

The occurrence at the treatment initiation of a feverish generalised erythema associated with pustula may be a symptom of acute generalised exanthemous pustulosis (AGEP).

This reaction requires amoxicillin discontinuation and contra-indicates any subsequent administration.

Amoxicillin should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.

The Jarisch-Herxheimer reaction has been seen following amoxicillin treatment of Lyme disease

It results directly from the bactericidal activity of amoxicillin on the causative bacteria of Lyme disease, the spirochaete *Borrelia burgdorferi*. Patients should be reassured that this is a common and usually self-limiting consequence of antibiotic treatment of Lyme disease.

Prolonged use of an anti-infective may result in the overgrowth of non-susceptible organisms (superinfection).

If antibiotic-associated colitis occur, amoxicillin should immediately be discontinued, a physician consulted and an appropriate therapy initiated. Anti-peristaltic medicinal products are contra-indicated in this situation.

Periodic assessment of organ system functions; including renal, hepatic and haematopoietic function is advisable during prolonged therapy.

Elevated liver enzymes and changes in blood counts have been reported Anticoagulants

Prolongation of prothrombin time has been reported rarely in patients receiving amoxicillin. Appropriate monitoring should be undertaken when anticoagulants are prescribed concomitantly.

Crystalluria has been observed very rarely, predominantly with parenteral therapy. During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin Crystalluria. In patients with bladder catheters, a regular check of patency should be maintained

Elevated serum and urinary levels of amoxicillin are likely to affect certain laboratory tests. Due to the high urinary concentrations of amoxicillin, false positive readings are common with chemical methods.

It is recommended that when testing for the presence of glucose in urine during amoxicillin treatment, enzymatic glucose oxidase methods should be used.

The presence of amoxicillin may distort assay results for oestriol in pregnant women.

Pregnancy ,Lactation and Fertility

Pregnancy: Amoxicillin may be used in pregnancy when the potential benefits outweigh the potential risks associated with treatment.

Breastfeeding : Amoxicillin is excreted into breast milk in small quantities with the possible risk of sensitisation. Consequently, diarrhoea and fungus infection of the mucous membranes are possible in the breast-fed infant, so that breast-feeding might have to be discontinued.

Amoxicillin should only be used during breast-feeding after benefit/risk assessment by the physician in charge.

Fertility :There are no data on the effects of amoxicillin on fertility in humans

Effects on ability to drive and use machines:

None known influence on the ability to drive and use machines.

Undesirable effects:

Very rare: Mucocutaneous candidiasis, Reversible leucopenia (including severe neutropenia or agranulocytosis), reversible thrombocytopenia and haemolytic anaemia., Prolongation of bleeding time and prothrombin time , Severe allergic reactions, including angioneurotic oedema, anaphylaxis, serum sickness and hypersensitivity vasculitis, Hyperkinesia, dizziness and convulsions , Antibiotic associated colitis (including pseudomembraneous colitis and haemorrhagic colitis , Black hairy tongue, Hepatitis and cholestatic jaundice. A moderate rise in AST and/or ALT

Skin reactions such as erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous and exfoliative dermatitis, acute generalised exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS), Interstitial nephritis, Crystalluria

Uncommon: Vomiting, Urticaria and pruritus

Not known: Jarisch-Herxheimer reaction

Overdose:

Symptoms and signs of overdose: Gastrointestinal symptoms (such as nausea, vomiting and diarrhoea) and disturbance of the fluid and electrolyte balances may be evident. Amoxicillin crystalluria, in some cases leading to renal failure, has been observed. Convulsions may occur in patients with impaired renal function or in those receiving high doses

Treatment of intoxication: Gastrointestinal symptoms may be treated symptomatically, with attention to the water/electrolyte balance.

Amoxicillin can be removed from the circulation by haemodialysis.

Shelf life: 3 years from the date of manufacture.

Special precautions for storage:

Stored in a dry place, below 30°C, Protected from light.

Keep all medicines out of reach of children.

Nature and contents of container:

Blister pack 10×10's in a unit carton and Bulk packs of 1000's or 500's in HDPE Jars

Marketing authorisation holder:

DAWA Limited,

Plot No. 7879/8, Baba Dogo Road, Ruaraka.

P. O. Box 16633 – 00620, Nairobi, Kenya

Marketing authorisation number(s):

Kenya registration number: H2006/632

Legal category: Prescription only medicine, (POM).

Manufactured by:

DAWA Limited, Plot No. 7879/8, Baba Dogo Road, Ruaraka
P. O. Box 16633 – 00620, Nairobi, Kenya.

Date of revision of the text

August 2018